Background
==========

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the third most frequent cause of death due to cancer \[[@B1]\]. Although the majority of cases are still found in Asia and Africa, recent evidence has shown that both incidence and mortality rate of HCC are rising in North America and Europe \[[@B2]-[@B4]\]. More than 75% of cases worldwide and 85% of cases in developing countries have been attributed to hepatitis B virus (HBV) and hepatitis C virus (HCV), both of which increase the risk of HCC about 20-fold \[[@B5]-[@B8]\]. Other well-recognized risk factors for HCC include advanced age, male gender, heavy alcohol drinking, aflatoxin exposure, tobacco smoking, cirrhosis, and some rare monogenic syndromes (for example, hemocromatosis, alpha1-antitrypsin deficiency, and porphyria cutanea tarda) \[[@B6]-[@B8]\]. Recent studies \[[@B5]-[@B8]\] demonstrated that a family history of liver cancer increases HCC risk, independent of HBV/HCV infection status. The combination of family history of liver cancer and positive HBV/HCV serum markers is associated with an elevated HCC risk of \>70-fold \[[@B8]\].

In the past decades the association between family history and cancer survival has been studied in various kinds of cancers, including colorectal cancer \[[@B9],[@B10]\], gastric cancer \[[@B11]\], breast cancer \[[@B12]\], and so on. Most of them demonstrated that a positive family history was associated with improved survival. Since the effect of a positive family history of HCC on the survival remains unclear, we performed the present study to evaluate the effect of family history on the clinicopathologic characteristics and prognosis of patients who received hepatectomy as initial treatment for HCC in a Chinese population.

Methods
=======

Ethics statement
----------------

The research was approved by the institutional review board (IRB) of Sun Yat-sen University Cancer Center, and written informed consent was obtained from each patient involved in the study.

Patients
--------

This is a retrospective study based on prospectively collected data at our hospital. Data on patients who underwent hepatectomy as initial treatment for HCC at the Department of Hepatobiliary Surgery, Sun Yat-Sen University Cancer Canter (Guangzhou, China) from 2000 to 2008 were retrieved from a prospective database. Only patients who met all of the following criteria were included: (1) no previous treatment for HCC before surgery; (2) histologic confirmation of HCC; (3) macroscopically completely resected, with a microscopically tumor-free margin proven by the pathology (R0 resection); (4) no lymph node or extrahepatic metastasis; (5) no history of other malignant disease; and (6) completed an interview about family history and health behavior. Since the current study aimed to analyze the prognostic factors for long-term survival, patients who died either perioperatively \<30 days following surgery or during the original hospital stay if \>30 days were excluded from this study.

All the preoperative parameters was recorded and evaluated as possible predictors of survivals including gender, age, HBV status, platelet count (PLT), prothrombin time (PT) alpha-fetoprotein (AFP), alanine transferase (ALT), total bilirubin level (TBIL), albumin (ALB), creatinine (Cr), liver function status, tumor size and number, and tumor thrombus. Liver functional reserve was also assessed using Child-Pugh classification. HBV positive was defined as HBsAg (+).

Family history assessment
-------------------------

Family history of HCC was ascertained by self-reporting through an interview at the time of index case diagnosis. Cases with family history of HCC in a first-degree relative were recognized as those having at least one first-degree relative with HCC. First-degree relatives include parents, siblings, or offspring. Family history in second-degree relatives was not assessed in present analysis. No questions were asked about family size.

Technique of hepatectomy
------------------------

Hepatectomy was carried out by using the techniques we described previously \[[@B13]\]. In brief, hepatectomy was carried out under general anesthesia using a right subcostal incision with midline extension. Intraoperative ultrasonography was routinely performed to confirm resectability and to visualize major vascular structures. Pringle's maneuver was routinely used with a clamp/unclamp time of 10/5 min. The liver parenchyma was divided with a clamp-crushing technique or ultrasonic dissector (CUSA) according to the surgeon's preference. Anatomic resection was our preferred surgical method in hepatic resection for multiple nodules in one segment or in neighboring segments. For anatomic resection, the hepatic parenchyma was transected at the intersegmental plane as described by Couinaud. For multiple bilobar nodules, anatomic resection was preferred for the main tumor, while satellite nodules were resected non-anatomically with intent for a negative resection margin. When an inadequate liver remnant was suspected, non-anatomic resection was performed with intent for a negative resection margin. Hemostasis on the raw liver surface was achieved with suturing and fibrin glue.

Follow-up
---------

Patients were followed up every 3 months for the first 2 years, then every 6 months thereafter with physical examination, blood tests for AFP and liver function, and contrast abdominal computed tomography (CT). Chest radiography was done every 6 months to detect lung metastasis. When metastasis was suspected, CT chest, bone scintigraphy, positron emission tomography (PET), and biopsy if indicated were also performed to confirm metastasis and/or recurrence. The last follow-up date for patients still alive was in October 2012.

Causes of death and sites of recurrence were determined from death certificates, medical interviews, and radiological findings. Overall survival (OS) was defined as the interval between surgery and time of either death or last follow-up. Disease-free survival (DFS) was defined as the length of time after liver resection for HCC to detectable intrahepatic and/or extrahepatic recurrence. The treatment for recurrent tumors was determined by our multidisciplinary team (MDT) made up of surgeons, oncologists, radiologists, hepatologists, and pathologists.

Statistical analyses
--------------------

The statistical analyses were performed using the SPSS 13.0 statistical software (SPSS Company, Chicago, IL, USA). The two groups were compared using student's t-test for continuous data and the Chi-square test for categorical data. The OS and DFS were calculated using the Kaplan-Meier method and compared using log-rank test. The prognostic factors in predicting OS and DFS were assessed by multivariate Cox proportional hazards regression analysis. All covariates that affected survival at the *P* \<0.10 level of significance in univariate analysis were included in a multivariate Cox proportional hazards model. Results were given as mean ± SD. All statistical tests were two-sided, and a significant difference was considered when *P* \<0.05.

Results
=======

Baseline characteristics
------------------------

A total of 1,427 patients with HCC who underwent hepatectomy as initial treatment were identified during the study period. Based on our inclusion criteria, 114 patients were excluded from this study, consisting of patients with lymph node metastasis (*n* = 11), positive resection margins (*n* = 77, 5.40%, 77/1,427), and those that died postoperatively (*n* = 26, mortality of 1.82%, 26/1,427).

Patients' baseline characteristics were summarized in Table  [1](#T1){ref-type="table"}. A total number of 1,313 patients were included in the study, including 169 patients (12.9%, 169/1,313) had a family history of HCC. The demographic and clinicopathologic characteristics of patients with or without a family history of HCC were compared, and no significant difference was identified between these two groups.

###### 

Clinicopathologic characteristics of the study population by family history

  **Variables**              **All (*n*= 1,313)**                        
  -------------------------- ---------------------- -------------------- -------
  Age (\>50/≤50 years)       54/115                 510/634              0.101
  Gender (M/F)               145/24                 1002/142             0.514
  ALT (u/L)                  45.7 ± 38.7            51.5 ± 55.7          0.192
  ALB (g/L)                  42.0 ± 6.8             41.7 ± 4.5           0.497
  TBIL (umol/L)              16.7 ± 9.7             18.7 ± 18.3          0.168
  Cr (umol/L)                93.0 ± 20.7            92.2 ± 28.2          0.078
  PT (s)                     13.3 ± 1.2             13.3 ± 1.3           0.644
  PLT count (×10^9^/L)       181.9 ±91.8            187.1 ± 76.9         0.837
  AFP (≤400/\>400 ng/mL)     98/71                  637/507              0.573
  HBV (positive/negative)    153/16                 959/185              0.220
  Liver cirrhosis (Yes/No)   149/20                 940/204              0.302
  Child Pugh (A/B)           167/2                  1123/21              0.546
  Tumor size (cm)            7.4 ± 4.2              7.3 ± 4.1            0.871
  Tumor number (1/\>1)       127/42                 867/277              0.857
  Major vascular invasion    19                     144                  0.621
  Micro vascular invasion    19                     125                  0.902
  Follow-up (months)         41.6 ± 32.8            44.7 ± 34.5          0.269
                             (range 2.0--136.0)     (range 2.0--142.0)    

*AFP* alpha-fetoprotein; *ALT* alanine transferase; *ALB* serum albumin; *Cr* creatinine; *HBV* hepatitis B virus; *PLT* platelets; *PT* prothrombin time; *TBIL* total bilirubin.

Effect of family history on survival
------------------------------------

The median follow-up period was 44 months (range 2.5-73.5 months). The 1-, 3-, and 5-year OS for all patients were 79.2%, 55.4%, and 45.5%, respectively, and the median OS was 47 months. The 1-, 3-, and 5-year DFS was 52.6%, 36.1%, and 31.8%, respectively, and the median DFS was 15 months.

Table  [2](#T2){ref-type="table"} summarized the OS and DFS of patients with or without a family history of HCC for all patients and subgroups according to TNM-7. For either OS or DFS, there was no significant difference in all patients nor in subgroups (Table  [2](#T2){ref-type="table"}, Figure  [1](#F1){ref-type="fig"}).

###### 

Overall and disease-free survival of the study population by family history and tumor stage

  **TMN**                       **Family history**   ***n***           **Overall survival**                                     
  ----------------------------- -------------------- ----------------- --------------------------- -------------- ------ ------ -------
  All                           Positive             169               43                          79.3           54.7   43.5   0.511
  Negative                      1,144                47                79.2                        55.5           45.8          
  I                             Positive             87                79                          87.4           71.0   58.9   0.282
  Negative                      623                  123               89.7                        71.0           58.9          
  II                            Positive             21                32                          81.0           44.2   36.8   0.441
  Negative                      146                  53                75.3                        55.9           48.6          
  III                           Positive             61                22                          67.7           34.7   24.8   0.550
  Negative                      375                  20                63.2                        29.9           23.0          
  **TMN**                       **Family history**   ***n***           **Disease-free survival**                                
  **Median survival (month)**   **1 year (%)**       **3 years (%)**   **5 years (%)**             ***P*value**                 
  All                           Positive             169               12                          50.3           33.8   27.6   0.231
                                Negative             1,144             14                          52.9           36.7   32.4   
  I                             Positive             87                28                          61.2           45.6   36.4   0.186
  Negative                      623                  35                66.8                        49.2           44.5          
  II                            Positive             21                4                           40.9           29.8   29.8   0.202
  Negative                      146                  12                49.0                        35.8           32.2          
  III                           Positive             61                7                           38.7           18.7   15.0   0.337
                                Negative             375               5                           31.5           16.2   12.2    

![Overall (a) and disease-free survival (b) for patients with or without family history.](1477-7819-11-280-1){#F1}

Since the synergism between HBV and a family history of HCC was noted by several studies, the OS and DFS of HBV positive patients with or without a family history of HCC were compared in Table  [3](#T3){ref-type="table"}. Similarly, for either OS or DFS, there was no significant difference in all patients nor in subgroups (Table  [3](#T3){ref-type="table"}, Figure  [2](#F2){ref-type="fig"}).

###### 

Overall and disease-free survival of HBV positive patients by family history and tumor stage

  **TMN**                       **Family history**   ***n***           **Overall survival**                                     
  ----------------------------- -------------------- ----------------- --------------------------- -------------- ------ ------ -------
  All                           Positive             153               43                          78.4           53.8   41.6   0.241
  Negative                      959                  46                79.1                        54.9           44.7          
  I                             Positive             77                79                          85.7           72.5   58.6   0.371
  Negative                      529                  105               90.2                        71.0           57.5          
  II                            Positive             19                31                          78.9           37.4   29.9   0.286
  Negative                      115                  48                73.0                        53.8           46.6          
  III                           Positive             57                22                          68.4           32.3   21.7   0.536
  Negative                      315                  19                62.9                        27.8           22.1          
  **TMN**                       **Family history**   ***n***           **Disease-free survival**                                
  **Median survival (month)**   **1 year (%)**       **3 years (%)**   **5 years (%)**             ***P*value**                 
  All                           Positive             153               13                          51.0           33.4   27.4   0.246
  Negative                      959                  16                53.1                        36.0           31.6          
  I                             Positive             77                28                          62.3           45.1   36.6   0.174
  Negative                      529                  34                67.7                        49.0           43.6          
  II                            Positive             19                4                           36.9           23.0   23.0   0.179
  Negative                      115                  12                48.7                        34.5           30.9          
  III                           Positive             57                8                           40.4           20.4   16.3   0.189
                                Negative             315               5                           30.2           14.5   11.5    

![Overall (a) and disease-free survival (b) for HBV positive patients with or without family history.](1477-7819-11-280-2){#F2}

It was also reported that a family history of HCC was only a risk factor in men but not women. The OS and DFS of male patients with or without a family history of HCC were compared in Figure  [3](#F3){ref-type="fig"}. Similarly, there was no significant difference in either OS or in DFS (*P* = 0.313 and *P* = 0.282, respectively, Figure  [3](#F3){ref-type="fig"}).

![Overall (a) and disease-free survival (b) for male patients with or without family history.](1477-7819-11-280-3){#F3}

Prognostic factors
------------------

All factors listed in Table  [1](#T1){ref-type="table"} were included in univariate analysis and the covariates that affected survival at the *P* \<0.10 level of significance in univariate analysis were included in a multivariate Cox proportional hazards model. Multivariate analysis showed that major vascular invasion (HR 2.624, 95% CI 2.149-3.203, *P* \<0.001), tumor size (HR 1.670, 95% CI 1.405-1.986, *P* \<0.001), tumor number (HR 1.569, 95% CI 1.333-1.846, *P* \<0.001), PT (HR 1.424, 95% CI 1.217-1.666, *P* \<0.001), ALB (HR 1.363, 95% CI 1.005-1.848, *P* = 0.046), PLT (HR 1.287, 95% CI 1.034-1.602, *P* = 0.024), and AFP (HR 1.179, 95% CI 1.011-1.375, *P* = 0.035) were significant prognostic factors for OS (Table  [4](#T4){ref-type="table"}).

###### 

Multivariate analysis of prognostic factors for overall and disease-free survival

  **Variables**                      **Overall survival**                        
  ---------------------------------- ---------------------------- -------------- ---------
  ALB (\>35 /≤35 g/L)                1.363                        1.005--1.848   0.046
  PT (\>15 /≤15 s)                   1.424                        1.217--1.666   \<0.001
  PLT count (\>100/≤100 × 10^9^/L)   1.287                        1.034--1.602   0.024
  AFP (≤400/\>400 ng/mL)             1.179                        1.011--1.375   0.035
  Tumor size (\>5 /≤5 cm)            1.670                        1.405--1.986   \<0.001
  Tumor number (1/\>1)               1.569                        1.333--1.846   \<0.001
  Major vascular invasion            2.624                        2.149--3.203   \<0.001
  **Variables**                      **Disease--free survival**                  
  **HR**                             **95.0% CI**                 ***P*value**   
  PT (\>15 /≤15 s)                   1.253                        1.092--1.438   0.001
  Tumor size (\>5 /≤5 cm)            1.541                        1.326--1.789   \<0.001
  Tumor number (1/\>1)               1.617                        1.397--1.872   \<0.001
  Major vascular invasion            2.456                        2.036--2.962   \<0.001
  Micro vascular invasion            1.338                        1.082--1.655   0.007

*AFP* alpha--fetoprotein; *ALB* serum albumin; *PLT* platelets; *PT* prothrombin time.

For DFS, multivariate analysis showed that major vascular invasion (HR 2.456, 95% CI 2.036-2.962, *P* \<0.001), tumor number (HR 1.617, 95% CI 1.397-1.872, *P* \<0.001), tumor size (HR 1.541, 95% CI 1.326-1.789, *P* \<0.001), micro vascular invasion (HR 1.338, 95% CI 1.082-1.655, *P* = 0.007), and PT (HR 1.253, 95% CI 1.092-1.438, *P* = 0.001) were significant prognostic factors (Table  [4](#T4){ref-type="table"}).

Family history was not a significant prognostic factor for either OS or DFS.

Discussion
==========

Numerous studies \[[@B8],[@B14]-[@B24]\] have demonstrated that a positive family history of liver cancer increases the risk of developing HCC. However, no previous studies have examined the influence of family history of liver cancer on subsequent outcomes in patients with established cancer. In this study, for the first time, we investigated the effect of family history on the clinicopathologic characteristics and prognosis of HCC. Our results showed that there was no significant difference in clinicopathologic characteristics and prognosis for patients with or without family history of HCC, either in all patients or in subgroups.

This study is based on family history as reported by patients, and only cases with a family history of HCC in first-degree relatives were included and analyzed. In the Connecticut Family Health Study \[[@B25]\], reports from first-degree relatives were more accurate than those from second-degree relatives, with positive predictive values between 78% and 80% for lung and breast cancer. Furthermore, several studies \[[@B5],[@B8],[@B14],[@B24]\] have shown that only the family history of HCC in first-degree relatives increases the risk of developing HCC, but not second-degree relatives. Thus, we considered only first-degree relatives and second-degree relatives were not assessed in this study. We observed that 169 of the 1,313 patients (12.9%) had a family history of HCC in first-degree relatives. Our results were similar to those previous epidemiologic studies from Asian, USA, and European populations. Yu et al. \[[@B13]\] from China demonstrated that 17.5% of 553 patients reported having first-degree family members with HCC. Hassan et al. \[[@B8]\] from the USA observed that 6.1% of the 347 patients with HCC reported having first-degree family members with liver cancer. In a case-control study in Italy \[[@B24]\], 37 of 284 HCC patients (13.0%) reported having first-degree relatives with liver cancer.

Family history of the disease was found to be associated with improved survival in some kinds of cancers \[[@B9]-[@B12]\], including colon cancer, breast cancer, and so on. However there was some controversy in regards to gastric cancer. Han et al. \[[@B11]\] and Palli et al. \[[@B26]\] reported that a positive family history of gastric cancer in first-degree relatives was associated with a decreased risk of death and recurrence in patients after adjustments for known prognostic factors. However, a report from Japan \[[@B27]\] found that a family history negatively affected survival among gastric cancer patients. In Taiwan \[[@B28]\], the survival curve of patients with a positive family history was similar to that of patients without a family history. In our study, the impact of family history of HCC on both OS and DFS were analyzed in all patients and in subgroups according to TNM-7 stage. However, no significant difference was identified in patients with or without family history of HCC in either OS or DFS, in all patients or in subgroups.

The synergism between HBV/HCV and a family history of HCC was noted by several studies \[[@B5],[@B8],[@B14],[@B24]\]. Turati et al. \[[@B24]\] reported that the combination of family history of liver cancer and HBV/HCV serum markers is associated to a \>70-fold elevated HCC risk. The prognosis of HBV-positive patients with or without a family history was compared in our study. Similarly, there was no significant difference in either OS or DFS, in all patients or in subgroups. Only a few patients (9.5%, 16/169) with a family history were HBV-negative, the survival of HBV-negative patients with or without a family history cannot be analyzed in the present study.

Hassan et al. \[[@B8]\] observed that family history of liver cancer was only a risk factor for HCC in men but not in women. Similar results were also shown in a prospective longitudinal 90,000-person cohort study in China \[[@B14]\] and a case-control study from Italy \[[@B15]\]. But Turati et al. \[[@B24]\] and two Japanese studies \[[@B20],[@B21]\] observed a non-significantly stronger association between HCC risk and family history of liver cancer for men. The OS and DFS of male patients with or without a family history of HCC were also compared in current study. However, no significant difference was identified either in OS or in DFS.

Several limitations of this study require commenting. First, as we relied on self-reported family history, misclassification of family history status may be possible. However, prior studies \[[@B25],[@B29]\] have demonstrated such data to be reliable. Moreover, because the data on family history were collected at study baseline before treatment, any errors in recall would have attenuated rather than exaggerated a true association with patient outcome. Second, we did not collect information regarding number of siblings, and the likelihood of having a family history of the disease may vary according to the number of siblings at risk for the disease. However, it is unlikely that family size independently affects survival. Another limitation is the lack of information on family history of chronic hepatitis, cirrhosis, and other inherited diseases such as genetic hemochromatosis and alpha-1-antitrypsin deficiency, which may be related to HCC risk and prognosis \[[@B30]-[@B32]\]. Third, because our study was based on a database in a single tertiary cancer center hospital and all patients received hepatectomy as initial treatment, our results may not be generalizable to a larger population of patients with HCC, or patients treated with other methods including transcather artery chemoembolization, local ablation therapy, systemic chemotherapy, and so on. However, the rate of family history in this cohort is similar to the general population of patients with HCC.

Finally, we cannot completely exclude the possibility that patients with a family history may experience an earlier detection of malignancy. However, the effect of family history persisted after adjusting for other patient and disease characteristics associated with cancer recurrence or survival. Additionally, administration of treatment, therapies for recurrence disease, and follow-up care were reasonably uniform among all participants. Moreover, the association between family history and survival remained largely unchanged across the TNM stage as well as HBV status.

Studies suggested the importance of genetic contributions to the development of HCC. However, the relationship between family history and outcome is likely to be complex and may be influenced by a confluence of genetic and environmental factors \[[@B33]-[@B35]\]. We considered whether shared environmental or lifestyle factors might contribute to our findings. Further investigation to explore the relationship between family history and these factors is required.

Conclusion
==========

Our results showed that there was no significant difference in clinicopathologic characteristics and prognosis for patients with HCC after hepatectomy with or without family history of HCC, either in all patients or in subgroups.
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